title: Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.
abstract: Due to the arrival of multi-valent HPV vaccines, it is more and more important to have a better understanding of the relationship between vaccination and screening programmes. This review aimed to: (1) collect published evidence on the cost-effectiveness profile of different HPV prevention strategies and, in particular, those combining vaccination with changes in screening practices; (2) explore the cost-effectiveness of alternative preventive strategies based on screening and vaccination.
  
  
  
  A systematic literature review was conducted in order to identify the relevant studies regarding the cost-effectiveness of prevention strategies against HPV infection. Analysis comparing the modelling approaches between studies was made along with an assessment of the magnitude of impact of several factors on the cost-effectiveness of different screening strategies.
  
  
  
  A total of 18 papers were quantitatively summarised within the narrative. A high degree of heterogeneity was found in terms of how HPV prevention strategies have been assessed in terms of their economic and epidemiological impact, with variation in screening practice and valence of HPV vaccination found to have large implications in terms of cost-effectiveness.
  
  
  
  This review demonstrated synergies between screening and vaccination. New prevention strategies involving multi-valence vaccination, HPV DNA test screening, delayed commencement and frequency of screening could be implemented in the future. Strategies implemented in the future should be chosen with care, and informed knowledge of the potential impact of all possible prevention strategies. Highlighted in this review is the difficulty in assessing multiple strategies. Appropriate modelling techniques will need to be utilised to assess the most cost-effective strategies.
authors.affiliation: Amaris, The Fitzpatrick Building, 188 York Way, London, N7 9AS, UK.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Gervais
authors.affiliation: Amaris, The Fitzpatrick Building, 188 York Way, London, N7 9AS, UK. kyle.dunton@amaris.com.
authors.forename: Kyle
authors.identifier: 0000-0002-1200-6755
authors.initials: K
authors.lastname: Dunton
authors.affiliation: Amaris, The Fitzpatrick Building, 188 York Way, London, N7 9AS, UK.
authors.forename: Yiling
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Sanofi Pasteur MSD, 162 avenue Jean Jaurès, CS 50712, 69367, Lyon, Cedex 07, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Largeron
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D014943:Global Health; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics* / Q000600:supply & distribution; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*; D014626:Vaginal Smears / Q000191:economics; D014932:Women's Health Services / Q000191:economics / Q000639:trends
chemical_list: D053918:Papillomavirus Vaccines
keywords: Cost-effectiveness; Human papillomavirus; Public health; Vaccination